1. **PURPOSE**
   1.1. This guidance describes a process that in general is suitable to document consent in writing.
   1.2. Other procedures may be suitable when approved by the IRB.

2. **BACKGROUND**
   2.1. “Person providing consent” means:
      2.1.1. In the case of a cognitive intact adult, the individual being asked to take part
      2.1.2. In the case of an adult unable to consent, that individual’s legal authorized
              representative (LAR)
      2.1.3. In the case of a child:
               2.1.3.1. One parent, if the other parent is deceased, unknown, incompetent, or
                        not reasonably available, or when only one parent has legal responsibility
                        for the care and custody of the child.
               2.1.3.2. One parent if the IRB determined that permission from one
                        parent was sufficient
               2.1.3.3. An individual who is authorized under applicable State or local
                        law to consent on behalf of a child to general medical care
               2.1.3.4. Both parents
      2.2. The short form of consent documentation may be use only if affirmatively approved
           by the IRB.
      2.3. For the short form of consent documentation:
           2.3.1. The short form is a standard template translated into the subject’s language.
           2.3.2. The summary is the English version of the long form.
      2.4. If the consent process required an **impartial witness**:
           2.4.1. The impartial witness is to be present during the entire consent discussion and
                   to attest that the information in the consent document and any other
                   information provided was accurately explained to, and apparently understood by,
                   the subject/LAR, and that consent was freely given.
           2.4.2. The impartial witness may not be a person involved in the research.

3. **GUIDANCE**
   3.1. If the consent process will be documented with the long form:
       3.1.1. Verify that the document is in language understandable to the person providing consent.
       3.1.2. If the IRB required written documentation of assent, note one of the following:
               3.1.2.1. Assent of the child was obtained.
3.1.2.2. Assent of the child was not obtained because the capability of the child is so limited that the child cannot reasonably be consulted.

3.1.3. Have the following individuals personally sign and date the consent document:

3.1.3.1. Person giving consent
3.1.3.2. Person obtaining consent
3.1.3.3. Impartial witness, if any

3.2. If the consent process will be documented with the short form:

3.2.1. Verify that the document is in language understandable to the person providing consent.

3.2.2. If the IRB required written documentation of assent, note one of the following:

3.2.2.1. Assent of the child was obtained.
3.2.2.2. Assent of the child was not obtained because the capability of the child is so limited that the child cannot reasonably be consulted.

3.2.3. Have the following individuals personally sign and date the consent document:

3.2.3.1. Person giving consent
3.2.3.2. Person obtaining consent
3.2.3.3. Impartial witness

3.2.4. Have the following individuals personally sign and date the summary:

3.2.4.1. Person giving consent
3.2.4.2. Person obtaining consent
3.2.4.3. Impartial witness

3.3. Provide the person providing consent with copies of the signed and dated documents.

3.3.1. This may be accomplished either by making a photocopy or by having individuals sign and date two copies.

3.4. File a copy of the consent document with the medical record when required by local policy.

3.5. Retain the signed and dated documents in the study records for the greater of:

3.5.1. Three years after completion of the research
3.5.2. For drug studies conducted under an investigational new drug (IND), two years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until two years after the investigation is discontinued and FDA is notified.
3.5.3. For device studies conducted under an integrated development environment (IDE) or abbreviated IDE, two years after the latter of the following two dates: The date on which the investigation is terminated or completed, or the date that the records are no longer required for purposes of supporting a premarket approval application or a notice of completion of a product development protocol.

3.5.4. The retention period requested by the sponsor.

3.5.5. The retention period required by local, state, or international law.

3.5.6. The retention period required by a site that is not part of Drexel University.

4. REFERENCES

4.1. 21 CFR §50.27, 56.115(b), §312.62(c), §812.140(d)

4.2. 45 CFR §46.115(b), §46.117